Trials / Completed
CompletedNCT03510572
Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
Clinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 Study
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The overall goal of this imaging trial is to evaluate \[18F\]PI-2620, a tau targeted positron emission computed tomography radioligand, in individuals with tauopathies and healthy volunteers (HV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]PI-2620 | Imaging for evaluating the accumulation of abnormal tau protein in the brain |
Timeline
- Start date
- 2018-06-04
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
- First posted
- 2018-04-27
- Last updated
- 2020-12-14
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03510572. Inclusion in this directory is not an endorsement.